Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05632380 | ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07661537 | A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 90 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 7, 2026 |
| NCT05990465 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06090864 | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | recruiting | Phase 1 / Phase 2 | 31 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma(COSTIMM) | recruiting | Phase 1 / Phase 2 | 186 | Regeneron PharmaceuticalsINDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03011814 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 78 | City of Hope Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 84 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | recruiting | Phase 1 / Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | recruiting | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05442515 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | recruiting | Phase 1 | 180 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 92 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07652281 | A Clinical Study of SHR-5421 in Patients With Multiple Myeloma | recruiting | Phase 1 | 97 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05365659 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | recruiting | Phase 1 | 140 | Iksuda Therapeutics Ltd.INDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT05773040 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | recruiting | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07730515 | Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 176 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | recruiting | Phase 1 | 46 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07099391 | A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06445517 | Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma | recruiting | Phase 1 | 60 | InSilico Medicine Hong Kong LimitedINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06699771 | Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies | recruiting | Phase 1 | 53 | GC Cell CorporationINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | recruiting | Phase 1 | 42 | LTZ Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT07200089 | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) | recruiting | Phase 1 | 52 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas(CABAL2) | recruiting | Phase 1 | 90 | Baylor College of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT07620314 | Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | recruiting | Phase 1 | 15 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05052528 | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 36 | University of California, DavisOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06565689 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 | recruiting | Phase 1 | 48 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06810778 | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07246707 | KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07532525 | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | recruiting | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients(STOMP) | recruiting | Phase 1 / Phase 2 | 300 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04656431 | Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma | recruiting | Phase 1 | 26 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05351593 | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | recruiting | Phase 1 / Phase 2 | 35 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07082868 | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | recruiting | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 210 | AbbVieINDUSTRY | 7 | Jul 13, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07302347 | A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) | recruiting | Phase 1 / Phase 2 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07583212 | Phase I Study of HRS-1635 in B-cell Malignancies | recruiting | Phase 1 | 180 | Chengdu Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2026source: clinicaltrials